Chakravarty Runu
ICMR Virus Unit, Kolkata, GB 4, 1st Floor ID and BG Hospital Campus, 57, Dr. Suresh Chandra Banerjee Road, Kolkata 700010, India.
Front Biosci (Schol Ed). 2011 Jan 1;3(1):156-67. doi: 10.2741/s141.
Chronic Hepatitis B (HBV) and Hepatitis C (HCV) virus infections are global health problems which may cause cirrhosis and even hepatocellular carcinoma. Hepatitis D virus (HDV) though a satellite virus of HBV, can also cause chronic infection. Serologic and molecular tools are needed for the diagnosis, monitoring and therapeutic management of chronic viral hepatitis associated with HBV, HDV and HCV. In HBV infection several serological markers are available for diagnosis and staging; while molecular assays are important for pretreatment evaluation, assessing drug response and identification of mutants. The endpoint of chronic HCV and HDV treatment is the sustained virological response, defined by an undetectable HCV/HDV RNA in serum with a sensitive assay 6 months after completion of treatment. HCV genotype and quantitative HCV RNA testing plays an important role in determining treatment duration, doses and also assess the likelihood of treatment response. Thus, virological assays are important in the diagnosis and management of individuals infected with chronic viral hepatitis.
慢性乙型肝炎（HBV）和丙型肝炎（HCV）病毒感染是全球性的健康问题，可能导致肝硬化甚至肝细胞癌。丁型肝炎病毒（HDV）虽是HBV的卫星病毒，但也可引起慢性感染。对于与HBV、HDV和HCV相关的慢性病毒性肝炎的诊断、监测和治疗管理，需要血清学和分子检测工具。在HBV感染中，有几种血清学标志物可用于诊断和分期；而分子检测对于治疗前评估、评估药物反应和突变体鉴定很重要。慢性HCV和HDV治疗的终点是持续病毒学应答，定义为在治疗完成6个月后，采用敏感检测方法在血清中检测不到HCV/HDV RNA。HCV基因型和HCV RNA定量检测在确定治疗疗程、剂量以及评估治疗反应可能性方面起着重要作用。因此，病毒学检测对于慢性病毒性肝炎感染者的诊断和管理很重要。
